P2, N=55, Completed, Imperial College London | Recruiting --> Completed | N=1300 --> 55

The design of TO-1187 was achieved by linking our previously reported HDAC6 inhibitor, TO-317, to the cereblon (CRBN) E3 ligase ligand, pomalidomide...In vivo evaluation confirmed that TO-1187 efficiently degraded HDAC6 in mouse tissues, measured 6 h after intravenous injection. In summary, TO-1187 represents a viable candidate for advanced preclinical evaluation of HDAC6 biology.

We administered different doses of letrozole to young, artificially menopausal female C57BL/6J mice and assessed pain sensation, emotion-related behaviors, and exercise endurance to identify the optimal AI dose and intervention period. Administration of diacerein partially alleviated pain-related behaviors. This model provides a valuable platform for exploring the cellular and molecular mechanisms of AI treatment and evaluating potential therapeutic interventions.

P2, N=120, Not yet recruiting, AbbVie

P1, N=167, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed

P2, N=200, Recruiting, AbbVie | Trial completion date: Apr 2027 --> Apr 2028 | Trial primary completion date: Apr 2027 --> Apr 2028

P2, N=110, Recruiting, Uma Borate | Trial primary completion date: Dec 2025 --> Dec 2028

P2, N=27, Terminated, Fondazione IRCCS Policlinico San Matteo di Pavia | N=40 --> 27 | Active, not recruiting --> Terminated; low patient enrollment rate

P=N/A, N=16, Not yet recruiting, Novartis Pharmaceuticals

In a Phase 1 study, TAVO103A was found to be safe, well tolerated, and demonstrated a median half-life of 63 days in healthy subjects. By recognizing a different epitope, TAVO103A provided more potent neutralization of IL-1β activities, a longer circulating half-life, and improved safety profiles compared to canakinumab, positioning it to be a potential best-in-class therapeutic option for various IL-1β-mediated diseases.

P2/3, N=460, Active, not recruiting, University Health Network, Toronto | Suspended --> Active, not recruiting | Trial completion date: Dec 2026 --> Mar 2025 | Trial primary completion date: May 2026 --> Mar 2025

In this study, we investigated the effects of pomalidomide, an immunomodulatory imide drug that induces the degradation of Ikaros and Aiolos, on HIV latency reversal and death of infected cells. Using CD4+ T cells from people living with HIV on suppressive antiretroviral therapy, as well as an in vitro model of productive HIV infection, we found that pomalidomide induced T cell activation and expression of stress proteins but no evidence of latency reversal or selective death of infected cells.

P2/3, N=460, Suspended, University Health Network, Toronto | N=1000 --> 460 | Recruiting --> Suspended

We also provide evidence that diacerein treatment of patient keratinocytes results in a downregulation of MMP-9 expression, accompanied by a reduction in their ability to degrade a fibrinogen matrix. These data characterize diacerein as a potential candidate for improving wound healing in RDEB through its impact on inflammatory as well as epithelial cells.

Previous data suggests almost one third of myeloma patients acquire mutations in the key IMiD effector cereblon by the time they are pomalidomide refractory. Dynamic modelling based on a newly generated crystal structure of the DDB1/CRBN/lenalidomide complex, with greater resolution than those published to date, helped to understand the impact of these mutations. These results have important implications for the interpretation of CRBN sequencing results from patients for future therapy decisions, particularly differentiating those who may, despite relapsing on IMiDs with CRBN mutations, have the potential to still benefit from the use of CELMoD agents.

P4, N=40, HenanCancerHospital; He'nan Cancer Hospital

P1/2, N=41, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Dec 2024 --> Mar 2025

P2, N=17, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Jan 2031 --> Feb 2029

P2, N=55, Terminated, Zhejiang DTRM Biopharma | N=120 --> 55 | Active, not recruiting --> Terminated; Despite the efforts of our dedicated team and initial progress, we were unable to secure the necessary financial resources to continue the study. We appreciate the support and participation of all involved.

P2, N=60, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting

Our findings revealed that the highly selective PTGES3 proteolysis is a potential therapeutic strategy for HCC, and PTGES3 degraders PTGES3-PROTACs can be developed as safe and effective drugs for HCC treatment.

P2, N=80, Recruiting, AbbVie | Not yet recruiting --> Recruiting

P=N/A, N=0, Available, Mayo Clinic

The molecules are based on connecting a known MYC binder to a VHL ligand or pomalidomide to induce MYC degradation in various cancer cells known to express MYC...Encouraging results presented herein suggest that the presented analogs may serve as prototype structures of future therapeutic agents for the treatment of MYC-dependent tumors. MYC protein degraders can well complement the more established inhibition approaches that have been presented in the past (e.g., disruption of the MYC-MAX complex formation by small-molecule inhibitors).

P2, N=60, Recruiting, R-Pharm International, LLC | Trial completion date: Aug 2026 --> Jan 2029 | Trial primary completion date: Aug 2026 --> Dec 2028

P2, N=31, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed

P=N/A, N=11, Not yet recruiting, University of California, San Francisco

P2/3, N=1000, Recruiting, University Health Network, Toronto | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: May 2025 --> May 2026

P2, N=84, Active, not recruiting, R-Pharm International, LLC | Recruiting --> Active, not recruiting | N=60 --> 84 | Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Aug 2024 --> Jan 2025

P2, N=80, Not yet recruiting, AbbVie

P2, N=124, Active, not recruiting, University of Leeds | Trial completion date: Jun 2023 --> Jun 2025

In addition, Nilsson J published the highest number of papers; Ridker PM and his article "Anti-inflammatory Therapy with Canakinumab for Atherosclerotic Disease" have played prominent roles...It not only assists researchers in grasping the current hotspots in this field but also reveals potential directions for future investigation. Moreover, future studies can optimize immunotherapy strategies based on hotspot predictions to decelerate the progression of atherosclerosis.

P2, N=17, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting

P3, N=128, Recruiting, TRB Chemedica | Trial completion date: Oct 2024 --> Dec 2026 | Trial primary completion date: Oct 2024 --> Dec 2026

However, canakinumab showed promise in a post-hoc analyses of patients with TET2-mutated CHIP, and other anti-inflammasome agents are actively under development or evaluation. In this review, we provide an overview of CHIP as a mediator of thromboembolic diseases and discuss emerging therapeutics aimed at intervening on this thrombo-inflammatory nexus.

P1/2, N=101, Active, not recruiting, University of Chicago | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2024 --> Nov 2025

P2, N=54, Completed, Amgen | Active, not recruiting --> Completed

Sequential post-hoc prospective single-cell RNA sequencing analyses of HSPCs and bone marrow mononuclear cells at different time points during therapy showed that canakinumab's on-target effects in hematopoietic populations expressing the IL-1β receptor decreased the TNF-mediated inflammatory signaling pathway but rescued ineffective erythropoiesis only in the context of lower genetic complexity. This study demonstrates that better stratification strategies could target lower-risk MDS patients more effectively.

P2/3, N=80, Suspended, R-Pharm Overseas, Inc. | Trial completion date: Oct 2025 --> Oct 2027 | Not yet recruiting --> Suspended | Trial primary completion date: May 2025 --> May 2027

P2, N=120, Not yet recruiting, Massachusetts General Hospital

P2, N=0, Withdrawn, R-Pharm Overseas, Inc. | N=14 --> 0 | Not yet recruiting --> Withdrawn

Plasma levels of tumor necrosis factor α and Interleukin-1 beta, as well as knee diameter, were significantly reduced in the treated groups compared to the untreated ones. Overall, the results suggest that the proposed DCN-loaded SMIOMPs represent a promising advancement in the arena of cartilage regeneration.